Page 16 - Mobile Android News Today

SAN FRANCISCO — Treatment with imatinib resulted in a sustained clinical benefit after 90 days in hospitalized patients with hypoxemic COVID-19, according to results of the CounterCOVID study.At the American Thoracic Society International Conference, Job R. Schippers, MD-PhD candidate for pulmonary medicine at Amsterdam University Medical Center, presented long-term clinical outcomes at 90

I often hear, “Hey, I know you from Twitter!” as I turn on my heels to identify the source. A variation of this exclamation has become commonplace at scientific conferences. Particularly in a time characterized by so much distance, the use of social media can be helpful for connecting with new areas of scholarship, fellow scientists and the people most affected by the work we do.

Although the development and use of biomarkers in liver transplantation has progressed in recent years, challenges and limitations remain, according to presenters at the American Transplant Congress 2022. Thomas D. Schiano, MD, professor of medicine and liver diseases at Mount Sinai in New York, told attendees that among transplant patients, biomarkers should monitor short- and long-term

Patients with psoriatic arthritis treated with bimekizumab demonstrated improvements across joint and skin parameters compared with placebo, according to Phase 3 clinical trial data presented at the EULAR 2022 Congress.“I am delighted to be able to present these very exciting Phase 3 data from the BE COMPLETE study of this inhibitor of both IL-17A and -F,” Joseph F. Merola, MD, of

The FDA has approved rituximab-arrx, in combination with methotrexate, in adult patients with moderate or severely active rheumatoid arthritis who have had inadequate responses to one or more TNF agonist therapies. Rituximab-arrx (Riabni, Amgen), a biosimilar to rituximab (Rituxan, Genentech) was previously approved for indications including non-Hodgkin’s lymphoma, chronic lymphocytic

Compared with living donors aged 50 to 70 years, donor age older than 70 years may be a negative predictor of kidney transplant and graft survival, according to a presentation at the American Transplant Congress.“I set out to see if the data and outcomes of a national cohort met my anecdotal findings that living kidney donor transplants from donors [older than] 70 years don’t perform

CHARLOTTE, N.C. — A history of COVID-19 nearly doubled the odds of having very short sleep, according to results from a large U.S. study presented at SLEEP 2022. “Few studies have focused on factors associated with sleep quantity and quality,” Marie-Rachelle Narcisse, PhD, lead study author and assistant professor at the University of Arkansas for Medical Sciences Northwest,

CHICAGO — In what researchers described as the first randomized controlled trial of chemotherapy in relapsed or refractory Ewing sarcoma, high-dose ifosfamide proved more effective in extending survival than topotecan and cyclophosphamide. Martin G. McCabe, MD, PhD, clinical senior lecturer in pediatric and adolescent oncology at University of Manchester in the U.K., presented the

CHICAGO — A combination of two targeted therapies significantly improved outcomes compared with standard care for children with BRAF V600 mutation-positive low-grade glioma, according to study results presented at ASCO Annual Meeting.Dabrafenib (Tafinlar, Novartis) and trametinib (Mekinist, Novartis) increased response rate, extended PFS and improved clinical benefit rate compared with

NEW ORLEANS — Risks for depression and suicidal ideation are higher among people with vs. without diabetes, and cases of suicide are likely underreported, according to a presenter at the American Diabetes Association Scientific Sessions. Katharine Barnard-Kelly, PhD, chief science officer at Spotlight Consultations in Portsmouth, U.K., professor at the Southern Health NHS Foundation